Reports Q3 revenue C$81.5M vs. C$72.28M last year. “I am excited to announce that for the nine months ended September 30, 2023, we reported record revenues and record adjusted EBITDA of over $254,000 and over $48,000, respectively, which represents a growth of 20% and 19%, respectively, over the same period last year, putting us on track to deliver record 2023 results. In addition, we advanced our product pipeline with the Brazilian pricing approval for Minjuvi which we expect to launch in the second quarter of 2024. We continue to execute on our mission to build a leading Pan-American ex US specialty pharmaceutical company by bringing innovative and branded generic products to our markets,” said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics Inc.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KHTRF:
- Knight Therapeutics Reports Third Quarter 2023 Results
- Is KHTRF a Buy, Before Earnings?
- Knight Therapeutics announces CMED price approval of Minjuvi in Brazil
- Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil
- Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil